ImmunityBio, Inc. — Form SCHEDULE 13D/A
Filed August 6, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Cambridge Equities, LP filed an amended Schedule 13D/A regarding ImmunityBio, Inc. The filing provides no specific details on share counts, percentages, dollar amounts, dates of transactions, or what substantive changes were made in this amendment. The document appears to be a procedural update to an earlier beneficial ownership disclosure.
Why this rating
Procedural amendment filing; lacks concrete transaction details, share counts, or ownership percentages to assess material change. Routine disclosure update.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.